Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789335 | 1.00 | KMT2A (0.43) | KMT2APOLBMEN1FABP5MMP2 | |
| SCHEMBL3783542 | 1.00 | KMT2A (0.43) | KMT2APOLBMEN1FABP5MMP2 | |
| SCHEMBL3793423 | 1.00 | KMT2A (0.43) | KMT2APOLBMEN1FABP5MMP2 | |
| SCHEMBL4249277 | 1.00 | KMT2A (0.43) | KMT2APOLBMEN1FABP5MMP2 | |
| Hydrochloric Acid SCHEMBL19819302 | 0.90 | ANPEP (0.50) | KMT2AFABP5MMP2ANPEPFABP7 | |
| Hydrochloric Acid SCHEMBL19815306 | 0.90 | ANPEP (0.50) | KMT2AFABP5MMP2ANPEPFABP7 | |
| SCHEMBL21895946 | 0.89 | FABP5 (0.46) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL29855006 | 0.89 | FABP5 (0.46) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL30861822 | 0.89 | FABP5 (0.46) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL30278686 | 0.89 | FABP5 (0.46) | KMT2AFABP5FABP7EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188231-B | Synthesis and application of pasireotide pentapeptide intermediate | 中国医学科学院药物研究所 | 2021-10-22 | — | — | CN | disclosed |
| CN-106188231-A | The synthesis of pasireotide pentapeptide intermediate and application | 中国医学科学院药物研究所 | 2016-12-07 | — | — | CN | disclosed |
| US-20100174096-A1 | Methods for Production of Optically Active Fluoropyrrolidine Derivatives | IM&T RESEARCH, INC. (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174096-A1 | Methods for Production of Optically Active Fluoropyrrolidine Derivatives | QDPR, FDPS, DPYD | KMT2A 4142/4885POLB 1745/4885MEN1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.